Sutro Biopharma, Inc.
STRO
$0.8578
$0.01021.20%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 147.98% | 33.76% | -86.98% | -49.66% | 146.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 147.98% | 33.76% | -86.98% | -49.66% | 146.89% |
| Cost of Revenue | -38.21% | -28.04% | -46.74% | 36.00% | 49.12% |
| Gross Profit | 170.00% | 53.70% | -19.79% | -86.43% | -16.47% |
| SG&A Expenses | -16.39% | 4.34% | -46.26% | -6.14% | -17.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.58% | -6.79% | 13.46% | 25.44% | 31.45% |
| Operating Income | 130.97% | 16.12% | -251.23% | -54.31% | -5.43% |
| Income Before Tax | 76.01% | -30.50% | -249.53% | -2.83% | -25.11% |
| Income Tax Expenses | -325.00% | -- | -85.10% | -- | -94.70% |
| Earnings from Continuing Operations | 76.05% | -30.50% | -333.20% | 1.01% | -24.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 76.05% | -30.50% | -333.20% | 1.01% | -24.64% |
| EBIT | 130.97% | 16.12% | -251.23% | -54.31% | -5.43% |
| EBITDA | 136.20% | 16.89% | -241.23% | -56.40% | -5.51% |
| EPS Basic | 77.00% | 3.49% | -272.33% | 26.89% | 7.41% |
| Normalized Basic EPS | 112.55% | 34.37% | -232.86% | -11.22% | 15.98% |
| EPS Diluted | 77.00% | 3.49% | -272.33% | 26.89% | 7.41% |
| Normalized Diluted EPS | 112.55% | 34.37% | -232.86% | -11.22% | 15.98% |
| Average Basic Shares Outstanding | 4.13% | 35.22% | 35.33% | 35.39% | 34.61% |
| Average Diluted Shares Outstanding | 4.13% | 35.22% | 35.33% | 35.39% | 34.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |